Song Yoo-Kyung, Kim Min-Ju, Kim Min-Soo, Lee Ji Hun, Chung Suk-Jae, Song Jin Sook, Chae Yoon-Jee, Lee Kyeong-Ryoon
Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology, Ochang 28116, Republic of Korea.
College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
Eur J Pharm Sci. 2022 Jun 1;173:106177. doi: 10.1016/j.ejps.2022.106177. Epub 2022 Mar 24.
Olaparib is a first-in-class poly (ADP-ribose) polymerase oral inhibitor used to treat various tumors. In this study, we clarified the roles of ABCB1/Abcb1 and ABCG2/Abcg2 transporters in restricting olaparib distribution to the brain. Olaparib was efficiently transported by human ABCG2, human ABCB1, and mouse Abcg2 in vitro. In the in vivo disposition study of olaparib using single or combination knockout mice, the systemic exposure of olaparib did not differ significantly between the strains over an 8-h period. However, the brain-to-plasma unbound concentration ratio of olaparib increased 5.6- and 8.1-fold in Abcb1a/1b and Abcb1a/1b;Abcg2 knockout mice, respectively, compared with wild-type mice. The Abcg2 single knockout mice exhibited a similar brain-to-plasma unbound concentration ratio to wild-type mice. Moreover, the brain distribution of olaparib could be modulated by the ABCB1/ABCG2 dual inhibitor elacridar to reach a similar degree of inhibition to Abcb1a/1b. These findings suggest that olaparib is actively transported by both human and mouse ABCB1/Abcb1 and ABCG2/Abcg2; while Abcb1a/1b is a major determinant of olaparib brain penetration in mice, Abcg2 is likely to be a minor contributor. Concomitant treatment with temozolomide slightly increased the brain distribution of olaparib in mouse, but the clinical impact of the interaction was expected to be limited.
奥拉帕利是首个用于治疗多种肿瘤的聚(ADP - 核糖)聚合酶口服抑制剂。在本研究中,我们阐明了ABCB1/Abcb1和ABCG2/Abcg2转运蛋白在限制奥拉帕利向脑内分布中的作用。在体外,人ABCG2、人ABCB1和小鼠Abcg2均能有效转运奥拉帕利。在使用单基因敲除或联合基因敲除小鼠进行的奥拉帕利体内处置研究中,在8小时内各品系间奥拉帕利的全身暴露量无显著差异。然而,与野生型小鼠相比,在Abcb1a/1b和Abcb1a/1b;Abcg2基因敲除小鼠中,奥拉帕利的脑 - 血浆非结合浓度比分别增加了5.6倍和8.1倍。Abcg2单基因敲除小鼠的脑 - 血浆非结合浓度比与野生型小鼠相似。此外,ABCB1/ABCG2双重抑制剂艾拉司群可调节奥拉帕利的脑内分布,达到与Abcb1a/1b基因敲除相似的抑制程度。这些发现表明,人和小鼠的ABCB1/Abcb1以及ABCG2/Abcg2均可主动转运奥拉帕利;虽然Abcb1a/1b是奥拉帕利在小鼠脑内渗透的主要决定因素,但Abcg2可能是次要因素。替莫唑胺联合治疗可使小鼠脑内奥拉帕利的分布略有增加,但这种相互作用的临床影响预计有限。